comparemela.com

Latest Breaking News On - Rare genetics - Page 1 : comparemela.com

Takeda Showcases Digital Health Solutions at G20 Meeting in India

Takeda Showcases Digital Health Solutions at G20 Meeting in India : Rashtra News Takeda Biopharmaceuticals India Private Limited Showcased Digital Innovations - MyPKFit, SYNAPSE and Athena at the G20 Health Working Group Meeting The Three-Day Meeting was Held in Goa, India, from April 17th to April 19th, 2023, and Side Event was Focused on: ‘Citizen-Centric

Ruchi sogarwalMansukh mandaviyaPuneet chopraGabriele ricciSerina fischerTakeda showcases digital health solutionsTakeda biopharmaceuticals india privateTakeda biopharmaceutical india pvt ltdHealth working groupDigital healthTakeda pharmaceutical companyHonble union healthHead of corporate affairsHealth working group meetingWorking groupThree day meeting

Takeda Enters Into Two-Year Contract with Canadian Blood Services for GLASSIA®, Treatment for Rare form of Emphysema - Takeda Pharmaceutical (NYSE:TAK)

Availability of GLASSIA® represents significant milestone for patients with emphysema due to severe hereditary deficiency of Alpha-1 antitrypsin TORONTO, Dec. 20, 2023 /CNW/ - Takeda Canada Inc. (Takeda) has

Angela dianoKen chapmanCanadian blood servicesHealth canadaTakeda pharmaceutical company limitedTakeda canada incUniversity health networkUniversity of torontoAsthma airway centreTakeda canadaRelated productsAirway centreExecutive directorProteinase inhibitorRute fernandesGeneral manager

Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases

Company to Feature 17 Company-Sponsored and Nine Collaborative Abstracts in Oncology and Hematology Hematology Presentations Include New Data from the Phase 3 and Continuation Trials Supporting.

San diegoUnited statesJohn cunninghamAwny farajallahGerman hodgkin study groupEuropean unionTakeda pharmaceutical company limitedTakeda pharmaceuticalsHealth canadaDrug administrationTakeda pharmaceuticals united statesa incExchange commissionImportant safety information european unionJapan ministry of healthEuropean medicines agencyTakeda pharmaceuticals international

New Campaign Celebrates Canadian Rare Disease Changemakers

/CNW/ - Today, 13 Canadian rare disease organizations, in partnership with Takeda Canada Inc. ("Takeda",) unite to launch I Am Number 12, to raise awareness of.

United statesKelly newellEmilita dela cruzAneal khanChristine whiteElisabeth lintonCanadian organization for rare disordersFoundation of canadaAssociation des patients immunodTakeda pharmaceutical company limitedTakeda canada incNational gaucher foundation of canadaCanadian fabry associationSickle cell disease association of canadaNational strategy for drugsTakeda canada

The European Commission Approves Label Update for TAKHZYRO® (lanadelumab), Expanding Its Use to a Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (HAE)

/PRNewswire/ Takeda (TSE:4502/NYSE:TAK) today announced the European Commission has approved TAKHZYRO® (lanadelumab) for the routine prevention of recurrent.

United kingdomUnited statesDidier relinPrnewswire takedaEuropean commissionEuropean medicines agencyTakeda pharmaceutical company limitedDrug administrationTakeda pharmaceutical companyHead of international regulatory at takedaEuropean commission decisionFirst routine prevention treatmentPatients underNew preventative treatment optionHereditary angioedemaEuropean economic area

vimarsana © 2020. All Rights Reserved.